Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Imaging with amyloid-β PET can potentially aid the early and accurate diagnosis of Alzheimer's disease. Florbetaben (¹⁸F) is a promising ¹⁸F-labelled amyloid-β-targeted PET tracer in clinical development. We aimed to assess the sensitivity and specificity of florbetaben (¹⁸F) PET in discriminating between patients with probable Alzheimer's disease and elderly healthy controls. Methods We did a multicentre, open-label, non-randomised phase 2 study in 18 centres in Australia, Germany, Switzerland, and the USA. Imaging with florbetaben (¹⁸F) PET was done on patients with probable Alzheimer's disease (age 55 years or older, mini-mental state examination [MMSE] score=18-26, clinical dementia rating [CDR]=0·5-2·0) and age-matched healthy controls (MMSE ≥ 28, CDR=0). Our primary objective was to establish the diagnostic efficacy of the scans in differentiating between patients with probable disease and age-matched healthy controls on the basis of neocortical tracer uptake pattern 90-110 min post-injection. PET images were assessed visually by three readers masked to the clinical diagnosis and all other clinical findings, and quantitatively by use of pre-established brain volumes of interest to obtain standard uptake value ratios (SUVRs), taking the cerebellar cortex as the reference region. This study is registered with ClinicalTrials.gov, number NCT00750282. Findings 81 participants with probable Alzheimer's disease and 69 healthy controls were assessed. Independent visual assessment of the PET scans showed a sensitivity of 80% (95% CI 71-89) and a specificity of 91% (84-98) for discriminating participants with Alzheimer's disease from healthy controls. The SUVRs in all neocortical grey-matter regions in participants with Alzheimer's disease were significantly higher (p Interpretation We provide verification of the efficacy, safety, and biological relevance of florbetaben (¹⁸F) amyloid-β PET and suggest its potential as a visual adjunct in the diagnostic algorithm of dementia. Funding Bayer Schering Pharma AG.

What this study adds

Evidence grade: High

This is a trial of 81 participants. This multicentre phase 2 diagnostic study found that florbetaben (18F) PET scans distinguished patients with probable Alzheimer's disease from healthy controls, with significantly higher tracer uptake in neocortical grey-matter regions in the Alzheimer's disease participants. The authors describe it as a potential visual adjunct in diagnosis, so it is a diagnostic imaging study, not a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Barthel, H., Gertz, H. J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., et al. (2011). Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(11)70077-1

Vancouver

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. The Lancet. Neurology. 2011. doi:10.1016/s1474-4422(11)70077-1. PMID: 21481640.

BibTeX

@article{barthel2011-21481640,
  author  = {Barthel, H. and Gertz, H. J. and Dresel, S. and Peters, O. and Bartenstein, P. and Buerger, K. and Hiemeyer, F. and Wittemer-Rump, S. M. and others},
  title   = {{Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study}},
  journal = {The Lancet. Neurology},
  year    = {2011},
  doi     = {10.1016/s1474-4422(11)70077-1},
  pmid    = {21481640},
  url     = {https://doi.org/10.1016/s1474-4422(11)70077-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This multicentre phase 2 diagnostic study found that florbetaben (18F) PET scans distinguished patients with probable Alzheimer's disease from healthy controls, with significantly higher tracer uptake in neocortical grey-matter regions in the Alzheimer's disease participants. The authors describe it as a potential visual adjunct in diagnosis, so it is a diagnostic imaging study, not a treatment or cure.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 8 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 70 of 100.70 of 100 points earned30 not earned

Published in a leading specialty journal, and it is a mid-stage phase 2 trial. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 8 / 12 A mid-stage phase 2 trial (from PubMed type “Clinical Trial, Phase II”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 1 / 4 81 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 593 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 34.9 citations a year over 17 year(s) since 2011
Impact for its field and year 5 / 6 Cited 24.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 39 other studies in this library
Still being cited 3 / 4 Cited 95 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Osama Sabri: h-index 70 (OpenAlex, whole career)
Institution's track record 1 / 3 Ludwig-Maximilians-Universität München: institution h-index 1,224 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21481640)
Free to read 0 / 2 Behind a paywall — scores zero
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

39 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →